Allogene Therapeutics explores cell therapy trial at ASTCT meeting

Traders Union
All News
Companies
Allogene Therapeutics at ASTCT

Top Stories

Editors' Picks

Crypto News

Financial News

Currencies

Market Voices

Billionaires

Companies

Regulators News

05.02.2026

Allogene Therapeutics explores cell therapy trial at ASTCT meeting — Allogene Therapeutics at ASTCT

Allogene Therapeutics shared their positive experience at the ASTCT Tandem Meetings in Salt Lake City, where they engaged with colleagues on the ALPHA3 trial.

This trial is evaluating the use of allogeneic CAR T-cell therapy in treating large B-cell lymphoma (LBCL). The company emphasized meaningful discussions on advancing this therapeutic frontier, heralding potential breakthroughs in cell therapy. The ALPHA3 trial is part of the ongoing exploration of innovative treatment methodologies for oncology.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Five years with Bitcoin: How El Salvador changed after legalizing BTC

By Eugene Komchuk
17 hours ago

Five years with Bitcoin: How El Salvador changed after legalizing BTC

Editors' Picks

Crypto on the court: How NBA Finals became a showcase for Ledger

By Anastasiia Chabaniuk
Yesterday

Crypto on the court: How NBA Finals became a showcase for Ledger

Editors' Picks

How to build wealth from scratch in 3 practical steps

By Johnathan Maverick
08.06.2026

How to build wealth from scratch in 3 practical steps

Editors' Picks

All Editors' Top Picks

Latest Allogene News

Allogene Therapeutics targets 1 in 3 LBCL relapses with ALPHA3 trial and MRD testing

By Artem Shendetskii
03.06.2026

Allogene Therapeutics targets 1 in 3 LBCL relapses with ALPHA3 trial and MRD testing

Companies

Allogene Therapeutics reviews investigational cema-cel use and early ALPHA3 safety data for community outpatients

By Eugene Komchuk
02.06.2026

Allogene Therapeutics reviews investigational cema-cel use and early ALPHA3 safety data for community outpatients

Companies

Allogene Therapeutics to present pipeline and strategy update at Jefferies Global Healthcare Conference

By Dmytro Kharkov
29.05.2026

Allogene Therapeutics to present pipeline and strategy update at Jefferies Global Healthcare Conference

Companies

All Allogene News

Eugene Komchuk
17 hours ago

Five years with Bitcoin: How El Salvador changed after legalizing BTC

Anastasiia Chabaniuk
Yesterday

Crypto on the court: How NBA Finals became a showcase for Ledger

Johnathan Maverick
08.06.2026

How to build wealth from scratch in 3 practical steps

Eugene Komchuk
08.06.2026

Kospi Index crash: Why South Korean market fell alongside AI stocks

Mira Kyivska
07.06.2026

Bitcoin or Ferrari: Which investment is better?

Hanna Syniavska
1 hour ago

Triple bearish divergence identified in Bitcoin uptrend, Jamie Coutts flags

Olga Shendetskaya
1 hour ago

Eggs now cost 6.8 percent of average hourly wage, Jeremy Horpedahl notes

Parshwa Turakhiya
1 hour ago

James Pethokoukis: Goldman Sachs flags conservative hyperscaler capex estimates for 2027

Ivan Andriyenko
1 hour ago

Matt Darling: U.K. furlough approach contrasts with U.S. unemployment insurance response

Elena Nikulina
1 hour ago

Promises made by advanced economies are fiscally unsustainable during zero growth, Hanno Lustig notes

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Olga Shendetskaya
11 hours ago

Hot CPI report puts new pressure on U.S. stocks

Hot CPI report puts new pressure on U.S. stocks

Igor Krasulya
12 hours ago

Kalshi adds XRP to regulated perpetual futures market

Kalshi adds XRP to regulated perpetual futures market

Olga Shendetskaya
13 hours ago

Global bond sales climb as defense spending and refinancing needs grow

Global bond sales climb as defense spending and refinancing needs grow

Hanna Syniavska
15 hours ago

SoftBank shares fall 8% as OpenAI-backed loan talks stall

SoftBank shares fall 8% as OpenAI-backed loan talks stall

Andrey Mastykin
16 hours ago

CLARITY Act talks hit new obstacles in Senate

CLARITY Act talks hit new obstacles in Senate

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Alphabet remains under pressure as AI drives growth outlook

Mykhailo Ihnatenko
Now

Tesla tests investor confidence amid tech sector sell-off

Anton Kharitonov
Now

Microsoft tests major support as pressure on shares persists after record expectations

Mykhailo Ihnatenko
Now

AMD retreats as AI rally cools and investors take profits

Anton Kharitonov
Now

Apple continues to decline as capex weighs on the stock

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.